Evaluation of Ischemic Modified Albumin Levels in Coronavirus Disease 2019-Positive and -Negative Patients with Acute Cardiac Injury

• Published in: Anatolian journal of cardiology Vol. 27; no. 12; pp. 706 - 711
• Main Authors: Ördekçi, Seyhan, Güler, Arda, Tekin Neijmann, Şebnem
• Format: Journal Article
• Language: English
• Published: Turkey 01.12.2023
• Subjects: Adult; Albumins; COVID-19; Heart Injuries; Humans; Prognosis; SARS-CoV-2
• ISSN: 2149-2263; 2149-2271
• DOI: 10.14744/AnatolJCardiol.2023.3431

The severe acute respiratory syndrome coronavirus 2 is the source of the global pandemic known as coronavirus disease 2019, and the disease prognosis is also linked to the prevalence of cardiac problems. In our study, we aimed to contribute to the early diagnosis and treatment of cardiac complications by evaluating ischemic modified albumin levels in adults with coronavirus disease 2019 disease. Our study was conducted with a total of 176 cases: group 1 (n = 70) with cardiac injury and coronavirus disease 2019 (+), group 2 (n = 57) with cardiac injury and coronavirus disease (-), and group 3 (n = 49) with healthy volunteers. The Mann-Whitney U test, the average, SD, minimum and maximum values, intergroup comparison of the results, and statistical significance were evaluated with the Pearson correlation coefficient. As a result of the bilateral comparisons, ischemic modified albumin measurements of the coronavirus disease 2019 (+) and coronavirus disease 2019 (-) groups were higher than the control group (P =.006 and P =.006, respectively). There was no statistically significant difference between ischemic modified albumin measurements of coronavirus disease 2019 (+) and coronavirus disease 2019 (-) groups. Ischemic modified albumin measurement accelerates the diagnosis and treatment process in the evaluation of cardiac injuries in coronavirus disease 2019 patients.